A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

Osama E. Rahma, Ed Ashtar, Malgorzata Czystowska, Marta E. Szajnik, Eva Wieckowski, Sarah Bernstein, Vincent E. Herrin, Mortada A. Shams, Seth M. Steinberg, Maria Merino, William Gooding, Carmen Visus, Albert B. DeLeo, Judith K. Wolf, Je Vrey G. Bell, Jay A. Berzofsky, Theresa L. Whiteside, Samir N. Khleif

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Purpose: Peptide antigens have been administered by different approaches as cancer vaccine therapy, including direct injection or pulsed onto dendritic cells; however, the optimal delivery method is still debatable. In this study, we describe the immune response elicited by two vaccine approaches using the wild-type (wt) p53 vaccine. Experimental design: Twenty-one HLA-A2.1 patients with stage III, IV, or recurrent ovarian cancer over-expressing the p53 protein with no evidence of disease were treated in two cohorts. Arm A received SC wt p53:264-272 peptide admixed with Montanide and GM-CSF. Arm B received wt p53:264-272 peptide-pulsed dendritic cells IV. Interleukin-2 (IL-2) was administered to both cohorts in alternative cycles. Results: Nine of 13 patients (69%) in arm A and 5 of 6 patients (83%) in arm B developed an immunologic response as determined by ELISPOT and tetramer assays. The vaccine caused no serious systemic side effects. IL-2 administration resulted in grade 3 and 4 toxicities in both arms and directly induced the expansion of T regulatory cells. The median overall survival was 40.8 and 29.6 months for arm A and B, respectively; the median progression-free survival was 4.2 and. 8.7 months, respectively. Conclusion: We found that using either vaccination approach generates comparable specific immune responses against the p53 peptide with minimal toxicity. Accordingly, our Wndings suggest that the use of less demanding SC approach may be as effective. Furthermore, the use of low-dose SC IL-2 as an adjuvant might have interfered with the immune response. Therefore, it may not be needed in future trials.

Original languageEnglish (US)
Pages (from-to)373-384
Number of pages12
JournalCancer Immunology, Immunotherapy
Volume61
Issue number3
DOIs
StatePublished - Mar 1 2012

Fingerprint

Subunit Vaccines
Subcutaneous Injections
Ovarian Neoplasms
Dendritic Cells
Interleukin-2
Recurrence
Peptides
Vaccines
Enzyme-Linked Immunospot Assay
Active Immunotherapy
Cancer Vaccines
Regulatory T-Lymphocytes
Granulocyte-Macrophage Colony-Stimulating Factor
Disease-Free Survival
Vaccination
Research Design
Antigens
Injections
Survival
Proteins

Keywords

  • Cancer vaccine
  • IL-2
  • Ovarian cancer
  • p53

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches : Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. / Rahma, Osama E.; Ashtar, Ed; Czystowska, Malgorzata; Szajnik, Marta E.; Wieckowski, Eva; Bernstein, Sarah; Herrin, Vincent E.; Shams, Mortada A.; Steinberg, Seth M.; Merino, Maria; Gooding, William; Visus, Carmen; DeLeo, Albert B.; Wolf, Judith K.; Bell, Je Vrey G.; Berzofsky, Jay A.; Whiteside, Theresa L.; Khleif, Samir N.

In: Cancer Immunology, Immunotherapy, Vol. 61, No. 3, 01.03.2012, p. 373-384.

Research output: Contribution to journalArticle

Rahma, OE, Ashtar, E, Czystowska, M, Szajnik, ME, Wieckowski, E, Bernstein, S, Herrin, VE, Shams, MA, Steinberg, SM, Merino, M, Gooding, W, Visus, C, DeLeo, AB, Wolf, JK, Bell, JVG, Berzofsky, JA, Whiteside, TL & Khleif, SN 2012, 'A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients', Cancer Immunology, Immunotherapy, vol. 61, no. 3, pp. 373-384. https://doi.org/10.1007/s00262-011-1100-9
Rahma, Osama E. ; Ashtar, Ed ; Czystowska, Malgorzata ; Szajnik, Marta E. ; Wieckowski, Eva ; Bernstein, Sarah ; Herrin, Vincent E. ; Shams, Mortada A. ; Steinberg, Seth M. ; Merino, Maria ; Gooding, William ; Visus, Carmen ; DeLeo, Albert B. ; Wolf, Judith K. ; Bell, Je Vrey G. ; Berzofsky, Jay A. ; Whiteside, Theresa L. ; Khleif, Samir N. / A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches : Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. In: Cancer Immunology, Immunotherapy. 2012 ; Vol. 61, No. 3. pp. 373-384.
@article{7f3d19b6b99c4eb59ead4e9294a44b9c,
title = "A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients",
abstract = "Purpose: Peptide antigens have been administered by different approaches as cancer vaccine therapy, including direct injection or pulsed onto dendritic cells; however, the optimal delivery method is still debatable. In this study, we describe the immune response elicited by two vaccine approaches using the wild-type (wt) p53 vaccine. Experimental design: Twenty-one HLA-A2.1 patients with stage III, IV, or recurrent ovarian cancer over-expressing the p53 protein with no evidence of disease were treated in two cohorts. Arm A received SC wt p53:264-272 peptide admixed with Montanide and GM-CSF. Arm B received wt p53:264-272 peptide-pulsed dendritic cells IV. Interleukin-2 (IL-2) was administered to both cohorts in alternative cycles. Results: Nine of 13 patients (69{\%}) in arm A and 5 of 6 patients (83{\%}) in arm B developed an immunologic response as determined by ELISPOT and tetramer assays. The vaccine caused no serious systemic side effects. IL-2 administration resulted in grade 3 and 4 toxicities in both arms and directly induced the expansion of T regulatory cells. The median overall survival was 40.8 and 29.6 months for arm A and B, respectively; the median progression-free survival was 4.2 and. 8.7 months, respectively. Conclusion: We found that using either vaccination approach generates comparable specific immune responses against the p53 peptide with minimal toxicity. Accordingly, our Wndings suggest that the use of less demanding SC approach may be as effective. Furthermore, the use of low-dose SC IL-2 as an adjuvant might have interfered with the immune response. Therefore, it may not be needed in future trials.",
keywords = "Cancer vaccine, IL-2, Ovarian cancer, p53",
author = "Rahma, {Osama E.} and Ed Ashtar and Malgorzata Czystowska and Szajnik, {Marta E.} and Eva Wieckowski and Sarah Bernstein and Herrin, {Vincent E.} and Shams, {Mortada A.} and Steinberg, {Seth M.} and Maria Merino and William Gooding and Carmen Visus and DeLeo, {Albert B.} and Wolf, {Judith K.} and Bell, {Je Vrey G.} and Berzofsky, {Jay A.} and Whiteside, {Theresa L.} and Khleif, {Samir N.}",
year = "2012",
month = "3",
day = "1",
doi = "10.1007/s00262-011-1100-9",
language = "English (US)",
volume = "61",
pages = "373--384",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",

}

TY - JOUR

T1 - A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches

T2 - Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

AU - Rahma, Osama E.

AU - Ashtar, Ed

AU - Czystowska, Malgorzata

AU - Szajnik, Marta E.

AU - Wieckowski, Eva

AU - Bernstein, Sarah

AU - Herrin, Vincent E.

AU - Shams, Mortada A.

AU - Steinberg, Seth M.

AU - Merino, Maria

AU - Gooding, William

AU - Visus, Carmen

AU - DeLeo, Albert B.

AU - Wolf, Judith K.

AU - Bell, Je Vrey G.

AU - Berzofsky, Jay A.

AU - Whiteside, Theresa L.

AU - Khleif, Samir N.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Purpose: Peptide antigens have been administered by different approaches as cancer vaccine therapy, including direct injection or pulsed onto dendritic cells; however, the optimal delivery method is still debatable. In this study, we describe the immune response elicited by two vaccine approaches using the wild-type (wt) p53 vaccine. Experimental design: Twenty-one HLA-A2.1 patients with stage III, IV, or recurrent ovarian cancer over-expressing the p53 protein with no evidence of disease were treated in two cohorts. Arm A received SC wt p53:264-272 peptide admixed with Montanide and GM-CSF. Arm B received wt p53:264-272 peptide-pulsed dendritic cells IV. Interleukin-2 (IL-2) was administered to both cohorts in alternative cycles. Results: Nine of 13 patients (69%) in arm A and 5 of 6 patients (83%) in arm B developed an immunologic response as determined by ELISPOT and tetramer assays. The vaccine caused no serious systemic side effects. IL-2 administration resulted in grade 3 and 4 toxicities in both arms and directly induced the expansion of T regulatory cells. The median overall survival was 40.8 and 29.6 months for arm A and B, respectively; the median progression-free survival was 4.2 and. 8.7 months, respectively. Conclusion: We found that using either vaccination approach generates comparable specific immune responses against the p53 peptide with minimal toxicity. Accordingly, our Wndings suggest that the use of less demanding SC approach may be as effective. Furthermore, the use of low-dose SC IL-2 as an adjuvant might have interfered with the immune response. Therefore, it may not be needed in future trials.

AB - Purpose: Peptide antigens have been administered by different approaches as cancer vaccine therapy, including direct injection or pulsed onto dendritic cells; however, the optimal delivery method is still debatable. In this study, we describe the immune response elicited by two vaccine approaches using the wild-type (wt) p53 vaccine. Experimental design: Twenty-one HLA-A2.1 patients with stage III, IV, or recurrent ovarian cancer over-expressing the p53 protein with no evidence of disease were treated in two cohorts. Arm A received SC wt p53:264-272 peptide admixed with Montanide and GM-CSF. Arm B received wt p53:264-272 peptide-pulsed dendritic cells IV. Interleukin-2 (IL-2) was administered to both cohorts in alternative cycles. Results: Nine of 13 patients (69%) in arm A and 5 of 6 patients (83%) in arm B developed an immunologic response as determined by ELISPOT and tetramer assays. The vaccine caused no serious systemic side effects. IL-2 administration resulted in grade 3 and 4 toxicities in both arms and directly induced the expansion of T regulatory cells. The median overall survival was 40.8 and 29.6 months for arm A and B, respectively; the median progression-free survival was 4.2 and. 8.7 months, respectively. Conclusion: We found that using either vaccination approach generates comparable specific immune responses against the p53 peptide with minimal toxicity. Accordingly, our Wndings suggest that the use of less demanding SC approach may be as effective. Furthermore, the use of low-dose SC IL-2 as an adjuvant might have interfered with the immune response. Therefore, it may not be needed in future trials.

KW - Cancer vaccine

KW - IL-2

KW - Ovarian cancer

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=84860790830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860790830&partnerID=8YFLogxK

U2 - 10.1007/s00262-011-1100-9

DO - 10.1007/s00262-011-1100-9

M3 - Article

C2 - 21927947

AN - SCOPUS:84860790830

VL - 61

SP - 373

EP - 384

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 3

ER -